Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury

Qi Joy Yang, Michael Kluger, Krzysztof Goryński, Janusz Pawliszyn, Barbara Bojko, Aiming Yu, Keumhan Noh, Markus Selzner, Angela Jerath, Stuart Mccluskey, K. Sandy Pang, Marcin Wasowicz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The liver and kidney functions of recipients of liver transplantation (LT) surgery with heart beating (HBD, n = 13) or living donors (LD, n = 9) with different cold ischemia times were examined during the neohepatic phase for the elimination of rocuronium bromide (ROC, cleared by liver and kidney) and tranexamic acid (TXA, cleared by kidney). Solid phase micro-extraction and LC-MS/MS was applied to determine the plasma concentrations of ROC and TXA, and creatinine was determined by standard laboratory methods. Metabolomics and the relative expressions of miR-122, miR-148a and γ-glutamyltranspeptidase (GGT), liver injury biomarkers, were also measured. The ROC clearance for HBD was significantly lower than that for LD (0.147 ± 0.052 vs. 0.265 ± 0.148 ml·min-1·g-1 liver) after intravenous injection (0.6 mg·kg-1). The clearance of TXA, a compound cleared by glomerular filtration, given as a 1 g bolus followed by infusion (10 mg·kg-1·h-1), was similar between HBD and LD groups (~ 1 ml·min-1·kg-1). The TXA clearance in both groups was lower than the GFR, showing a small extent of hepatorenal coupling. The miR-122 and miR-148a expressions were similar for the HBD and LD groups, whereas GGT expression was significantly increased for HBD. The lower ROC clearance and the higher GGT levels in the HBD group of longer cold ischemia times performed worse than the LD group during the neophase. Metabololmics further showed clusters of bile acids, phospholipids and lipid ω-oxidation products for the LD and HBD groups. In conclusion, ROC CL and GGT expression, and metabolomics could serve as sensitive indices of early graft function.

Original languageEnglish (US)
JournalBiopharmaceutics and Drug Disposition
DOIs
StateAccepted/In press - 2017

Fingerprint

Living Donors
Biomarkers
Transplants
Cold Ischemia
Metabolomics
Liver
Wounds and Injuries
Kidney
Tranexamic Acid
Solid Phase Extraction
Bile Acids and Salts
Intravenous Injections
Liver Transplantation
Thoracic Surgery
Creatinine
Phospholipids
Lipids

Keywords

  • Biomarkers and metabolomics
  • Heart beating and living donors
  • Liver and kidney function
  • Liver transplantation
  • Rocuronium bromide and tranexamic acid clearance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Comparing early liver graft function from heart beating and living-donors : A pilot study aiming to identify new biomarkers of liver injury. / Yang, Qi Joy; Kluger, Michael; Goryński, Krzysztof; Pawliszyn, Janusz; Bojko, Barbara; Yu, Aiming; Noh, Keumhan; Selzner, Markus; Jerath, Angela; Mccluskey, Stuart; Pang, K. Sandy; Wasowicz, Marcin.

In: Biopharmaceutics and Drug Disposition, 2017.

Research output: Contribution to journalArticle

Yang, Qi Joy ; Kluger, Michael ; Goryński, Krzysztof ; Pawliszyn, Janusz ; Bojko, Barbara ; Yu, Aiming ; Noh, Keumhan ; Selzner, Markus ; Jerath, Angela ; Mccluskey, Stuart ; Pang, K. Sandy ; Wasowicz, Marcin. / Comparing early liver graft function from heart beating and living-donors : A pilot study aiming to identify new biomarkers of liver injury. In: Biopharmaceutics and Drug Disposition. 2017.
@article{c7d8d96f945a4c8db5f3525d90cc946e,
title = "Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury",
abstract = "The liver and kidney functions of recipients of liver transplantation (LT) surgery with heart beating (HBD, n = 13) or living donors (LD, n = 9) with different cold ischemia times were examined during the neohepatic phase for the elimination of rocuronium bromide (ROC, cleared by liver and kidney) and tranexamic acid (TXA, cleared by kidney). Solid phase micro-extraction and LC-MS/MS was applied to determine the plasma concentrations of ROC and TXA, and creatinine was determined by standard laboratory methods. Metabolomics and the relative expressions of miR-122, miR-148a and γ-glutamyltranspeptidase (GGT), liver injury biomarkers, were also measured. The ROC clearance for HBD was significantly lower than that for LD (0.147 ± 0.052 vs. 0.265 ± 0.148 ml·min-1·g-1 liver) after intravenous injection (0.6 mg·kg-1). The clearance of TXA, a compound cleared by glomerular filtration, given as a 1 g bolus followed by infusion (10 mg·kg-1·h-1), was similar between HBD and LD groups (~ 1 ml·min-1·kg-1). The TXA clearance in both groups was lower than the GFR, showing a small extent of hepatorenal coupling. The miR-122 and miR-148a expressions were similar for the HBD and LD groups, whereas GGT expression was significantly increased for HBD. The lower ROC clearance and the higher GGT levels in the HBD group of longer cold ischemia times performed worse than the LD group during the neophase. Metabololmics further showed clusters of bile acids, phospholipids and lipid ω-oxidation products for the LD and HBD groups. In conclusion, ROC CL and GGT expression, and metabolomics could serve as sensitive indices of early graft function.",
keywords = "Biomarkers and metabolomics, Heart beating and living donors, Liver and kidney function, Liver transplantation, Rocuronium bromide and tranexamic acid clearance",
author = "Yang, {Qi Joy} and Michael Kluger and Krzysztof Goryński and Janusz Pawliszyn and Barbara Bojko and Aiming Yu and Keumhan Noh and Markus Selzner and Angela Jerath and Stuart Mccluskey and Pang, {K. Sandy} and Marcin Wasowicz",
year = "2017",
doi = "10.1002/bdd.2066",
language = "English (US)",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Comparing early liver graft function from heart beating and living-donors

T2 - A pilot study aiming to identify new biomarkers of liver injury

AU - Yang, Qi Joy

AU - Kluger, Michael

AU - Goryński, Krzysztof

AU - Pawliszyn, Janusz

AU - Bojko, Barbara

AU - Yu, Aiming

AU - Noh, Keumhan

AU - Selzner, Markus

AU - Jerath, Angela

AU - Mccluskey, Stuart

AU - Pang, K. Sandy

AU - Wasowicz, Marcin

PY - 2017

Y1 - 2017

N2 - The liver and kidney functions of recipients of liver transplantation (LT) surgery with heart beating (HBD, n = 13) or living donors (LD, n = 9) with different cold ischemia times were examined during the neohepatic phase for the elimination of rocuronium bromide (ROC, cleared by liver and kidney) and tranexamic acid (TXA, cleared by kidney). Solid phase micro-extraction and LC-MS/MS was applied to determine the plasma concentrations of ROC and TXA, and creatinine was determined by standard laboratory methods. Metabolomics and the relative expressions of miR-122, miR-148a and γ-glutamyltranspeptidase (GGT), liver injury biomarkers, were also measured. The ROC clearance for HBD was significantly lower than that for LD (0.147 ± 0.052 vs. 0.265 ± 0.148 ml·min-1·g-1 liver) after intravenous injection (0.6 mg·kg-1). The clearance of TXA, a compound cleared by glomerular filtration, given as a 1 g bolus followed by infusion (10 mg·kg-1·h-1), was similar between HBD and LD groups (~ 1 ml·min-1·kg-1). The TXA clearance in both groups was lower than the GFR, showing a small extent of hepatorenal coupling. The miR-122 and miR-148a expressions were similar for the HBD and LD groups, whereas GGT expression was significantly increased for HBD. The lower ROC clearance and the higher GGT levels in the HBD group of longer cold ischemia times performed worse than the LD group during the neophase. Metabololmics further showed clusters of bile acids, phospholipids and lipid ω-oxidation products for the LD and HBD groups. In conclusion, ROC CL and GGT expression, and metabolomics could serve as sensitive indices of early graft function.

AB - The liver and kidney functions of recipients of liver transplantation (LT) surgery with heart beating (HBD, n = 13) or living donors (LD, n = 9) with different cold ischemia times were examined during the neohepatic phase for the elimination of rocuronium bromide (ROC, cleared by liver and kidney) and tranexamic acid (TXA, cleared by kidney). Solid phase micro-extraction and LC-MS/MS was applied to determine the plasma concentrations of ROC and TXA, and creatinine was determined by standard laboratory methods. Metabolomics and the relative expressions of miR-122, miR-148a and γ-glutamyltranspeptidase (GGT), liver injury biomarkers, were also measured. The ROC clearance for HBD was significantly lower than that for LD (0.147 ± 0.052 vs. 0.265 ± 0.148 ml·min-1·g-1 liver) after intravenous injection (0.6 mg·kg-1). The clearance of TXA, a compound cleared by glomerular filtration, given as a 1 g bolus followed by infusion (10 mg·kg-1·h-1), was similar between HBD and LD groups (~ 1 ml·min-1·kg-1). The TXA clearance in both groups was lower than the GFR, showing a small extent of hepatorenal coupling. The miR-122 and miR-148a expressions were similar for the HBD and LD groups, whereas GGT expression was significantly increased for HBD. The lower ROC clearance and the higher GGT levels in the HBD group of longer cold ischemia times performed worse than the LD group during the neophase. Metabololmics further showed clusters of bile acids, phospholipids and lipid ω-oxidation products for the LD and HBD groups. In conclusion, ROC CL and GGT expression, and metabolomics could serve as sensitive indices of early graft function.

KW - Biomarkers and metabolomics

KW - Heart beating and living donors

KW - Liver and kidney function

KW - Liver transplantation

KW - Rocuronium bromide and tranexamic acid clearance

UR - http://www.scopus.com/inward/record.url?scp=85017402870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017402870&partnerID=8YFLogxK

U2 - 10.1002/bdd.2066

DO - 10.1002/bdd.2066

M3 - Article

C2 - 28102538

AN - SCOPUS:85017402870

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

ER -